TIGER'S TAKE: On our trading list, the good news keeps coming in for IOVA. A very nice performer this year so far. $IOVAIovance Biotherapeutics analyst commentary at H.C. WainwrightH.C. Wainwright reiterates Buy, $32 price target on Iovance. H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Iovance Biotherapeutics with a $32 price target after the company disclosed updates regarding the regulatory path for LN-145 in cervical cancer. With the possibility for innovaTIL-04 study to be registrational, the company is "reasonably" planning a path for a Biologics License Application submission in the second half of 2020, Pantginis tells investors in a research note. The analyst believes LN-145 "deserves the attention it is receiving." While the primary focus remains on Iovance's initial path to market with lifileucel in melanoma, LN-145 is a "potential rapid follower to commercialization," says Pantginis.Source: (thefly.com)Iovance Biotherapeutics analyst commentary at Piper JaffrayIovance submission on track for second half of 2020, says Piper Jaffray. Piper Jaffray analyst Joseph Catanzaro says guidance from the FDA, as announced this morning by the company, puts Iovance Biotherapeutics on track for a Biologics License Application in cervical cancer in the second half of 2020. This is a positive outcome and largely in-line with where consensus has moved following the ASCO presentation, Catanzaro tells investors in a research note. He maintains an Overweight rating on Iovance Biotherapeutics with a $30 price target.Source: (thefly.com) $IOVA, Iovance Biotherapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page.